Literature DB >> 25621192

Intravitreal Anti-Vascular Endothelial Growth Factor in Retinopathy of Prematurity: Several Years On.

Andreas K Lauer.   

Abstract

Entities:  

Year:  2014        PMID： 25621192      PMCID： PMC4303567          DOI： 10.1097/APO.0000000000000099

Source DB:  PubMed          Journal:  Asia Pac J Ophthalmol (Phila)        ISSN： 2162-0989


× No keyword cloud information.
  15 in total

1.  Growth factor levels and ROP.

Authors:  Enrique Villegas Becerril; Rafael Gonzalez Fernández; Francisco Fernández Molina; José María Gallardo Galera
Journal:  Ophthalmology       Date:  2005-12       Impact factor: 12.079

2.  Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture.

Authors:  Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-15       Impact factor: 4.799

3.  Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1988-04

4.  Intravitreal Bevacizumab in Retinopathy of Prematurity: Inject or Not?

Authors:  Dini Hapsari; Rita S Sitorus
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2014 Nov-Dec

5.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

Authors:  Helen A Mintz-Hittner; Kathleen A Kennedy; Alice Z Chuang
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

6.  Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.

Authors:  William V Good
Journal:  Trans Am Ophthalmol Soc       Date:  2004

7.  Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

Authors: 
Journal:  Arch Ophthalmol       Date:  2003-12

8.  Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story.

Authors:  Hugo Quiroz-Mercado; Orlando Ustariz-González; Maria A Martinez-Castellanos; Paola Covarrubias; Francisca Dominguez; Valeria Sanchez-Huerta
Journal:  Semin Ophthalmol       Date:  2007 Apr-Jun       Impact factor: 1.975

9.  Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity.

Authors:  Geeta A Lalwani; Audina M Berrocal; Timothy G Murray; Maria Buch; Scott Cardone; Ditte Hess; Rose A Johnson; Carmen A Puliafito
Journal:  Retina       Date:  2008-03       Impact factor: 4.256

10.  Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability.

Authors:  Kenichi Kimoto; Toshiaki Kubota
Journal:  J Ophthalmol       Date:  2011-11-03       Impact factor: 1.909
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.